|
|
Article: XOMA Gets More Loan Money In Raptiva Deal With Genentech.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Gearing up for an approval of the psoriasis drug Raptiva by year's end, Genentech Inc. and XOMA Ltd. have retooled their agreement, with the former financing the latter's development costs $80 million at a time.
"There's been some misperception that Genentech is handing over $95 million in loans," said Laura Zobkiw, corporate communications manager for Berkeley, Calif.-based XOMA, but the deal has not been altered by much.
"Basically, the credit limit from the original agreement has been increased, and there's a new commercial loan," she said. "This is mainly housekeeping to address and reflect current circumstances."
...
Related newspaper, magazine, and journal articles:
|
|
Article: RAPTIVA PRELIMINARY DATA POOR IN PSORIATIC ARTHRITIS PHASE ...
BIOWORLD Today;
March 23, 2004 ;
700+ words
... ... spokeswoman, told BioWorld Today the company is ... have faith in Raptiva, an FDA-approved ... phototherapy. (See BioWorld Today, Oct. 29 ... Genentech, told BioWorld Today the trial likely ... in psoriasis. Raptiva is designed to ...
|
|